These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2351315)

  • 21. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
    Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
    Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
    J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
    Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; O'Toole RV; Abbott TM; Kronmal R; Hilgers RD; Surwit EA; Eyre HJ; Baker LH
    Gynecol Oncol; 1989 Jan; 32(1):16-21. PubMed ID: 2642453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
    Hofstetter G; Concin N; Braicu I; Chekerov R; Sehouli J; Cadron I; Van Gorp T; Trillsch F; Mahner S; Ulmer H; Grimm C; Castillo-Tong DC; Zeillinger R; Zeimet AG; Vergote I
    Gynecol Oncol; 2013 Oct; 131(1):15-20. PubMed ID: 23877013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
    J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils JA
    Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
    Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
    Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.